注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Aldeyra Therapeutics Inc是一家生物技术公司,致力于开发免疫调节疗法来治疗眼部和全身性疾病。该公司的主要候选产品reproxalap是一种治疗干眼病(DED)和过敏性结膜炎(AC)的后期开发药物。该公司还有其他正在开发中的候选产品,这些产品用于治疗增殖性玻璃体视网膜病变(PVR)、原发性玻璃体视网膜淋巴瘤(PVRL)和其他视网膜疾病、自身免疫性疾病和癌症。该公司的产品开发管线专注于免疫介导的眼部疾病和选择全身性疾病,包括两种生物学作用机制:活性醛类(RASP)调节和二氢叶酸还原酶抑制。其候选产品的免疫活性通常通过下调免疫细胞激活或增殖引起病理炎症水平降低。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Ben R. Bronstein | 71 | 2010 | Independent Director |
Martin J. Joyce | 67 | 2013 | Independent Director |
Paul M. Karpecki | 54 | 2020 | Member of Anterior Segment Scientific Advisory Board |
Gary M. Phillips | 55 | 2009 | Independent Director |
Richard Huntington Douglas | 68 | 2016 | Independent Chair of the Board |
Todd C. Brady | 49 | 2005 | CEO, President & Director |
David Chu | - | - | Member of Anterior Segment Scientific Advisory Board |
Nancy Miller-Rich | 62 | 2020 | Independent Director |
Neal S. Walker | 51 | 2013 | Independent Director |
John J. Sheppard | - | - | Member of Anterior Segment Scientific Advisory Board |
Jay S. Duker | 63 | - | Member of Retina Segment Scientific Advisory Board |
Jeffrey S. Heier | 61 | - | Member of Retina Segment Scientific Advisory Board |
Quan Dong Nguyen | - | - | Member of Retina Segment Scientific Advisory Board |
Carl D. Regillo | - | - | Member of Retina Segment Scientific Advisory Board |
Victor Perez | - | - | Member of Anterior Segment Scientific Advisory Board |
Dean Eliott | - | - | Member of Retina Segment Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核